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The Histamine H4 Receptor Mediates Inflammation
and Pruritus in Th2-Dependent Dermal Inflammation
Jeffery M. Cowden1,2, Mai Zhang1,2, Paul J. Dunford1 and Robin L. Thurmond1
The role of histamine H4 receptor (H4R) was investigated in a T-helper type 2 (Th2)-cell-mediated mouse skin
inflammation model that mimics several of the features of atopic dermatitis. Treatment with two specific H4R
antagonists before challenge with FITC led to a significant reduction in ear edema, inflammation, mast cell, and
eosinophil infiltration. This was accompanied by a reduction in the levels of several cytokines and chemokines
in the ear tissue. Upon ex vivo antigen stimulation of lymph nodes, H4R antagonism reduced lymphocyte
proliferation and IL-4, IL-5, and IL-17 levels. One explanation for this finding is that lymph nodes from animals
dosed with the H4R antagonist, JNJ 7777120, contained a lower number of FITC-positive dendritic cells. The
effect of H4R antagonism on dendritic cell migration in vivo may be an indirect result of the reduction in tissue
cytokines and chemokines or a direct effect on chemotaxis. In addition to anti-inflammatory effects, JNJ 7777120
also significantly inhibited the pruritus shown in the model. Therefore, the dual effects of H4R antagonists
on pruritus and Th2-cell-mediated inflammation point to their therapeutic potential for the treatment of
Th2-mediated skin disorders, including atopic dermatitis.
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INTRODUCTION
The histamine H4 receptor (H4R) is the most recently
described histamine receptor and is primarily expressed on
hematopoietic cells, in particular, dendritic cells, mast cells,
and eosinophils (for a recent review, see Huang and
Thurmond, 2008). The H4R exerts profound effects in
regulating immune cell functions, that is, chemotaxis,
cytokine, and chemokine expression (Huang and Thurmond,
2008). A number of in vivo studies have shown H4R
involvement in both innate and adaptive immune responses
(Thurmond et al., 2004; Varga et al., 2005; Dunford et al.,
2006; Coruzzi et al., 2007). In particular, the H4R has been
shown to mediate T helper type 2 (Th2) responses in vivo and
in vitro and antagonists of the receptor reduce lung
inflammation in a mouse model of allergic asthma (Dunford
et al., 2006). These, and other lines of evidence, make H4R a
promising immunomodulatory target for the treatment of
allergic, autoimmune, and other inflammatory diseases
(Huang and Thurmond, 2008; Thurmond et al., 2008). In
addition to its effects in inflammation, the H4R has also been
shown to direct pruritic responses in mice (Bell et al., 2004;
Dunford et al., 2007; Rossbach et al., 2009). This dual effect
on allergic inflammation and pruritus suggests that the H4R is
a promising new therapeutic target for treating allergic skin
diseases such as atopic dermatitis.
Atopic dermatitis is a common chronic inflammatory skin
disease with symptoms that include skin lesions, pruritus, and
dry skin (for recent reviews, see Akdis et al., 2006; Homey
et al., 2006; Bieber, 2008). The condition is often predictive
of subsequent atopic disorders such as allergic rhinitis and
asthma. All atopic diseases share certain pathogenic and
immunologic elements such as eosinophilia and elevated IgE
levels (Spergel and Paller, 2003; Cookson, 2004; Avgerinou
et al., 2008). Atopic dermatitis is believed to be driven, at
least in the early stages, by Th2 cell responses, because
lesions show marked T-cell infiltration and these cells
predominantly express IL-4, IL-5, and IL-13, especially during
the acute phase, but Th1 responses may have a more
dominant role in chronic lesions (Akdis et al., 2006; Homey
et al., 2006; Bieber, 2008).
Histamine is recognized as a major inflammatory mediator
released by mast cells, basophils, and other cells during
allergic reactions and exerts its actions through four distinct
G-protein-coupled receptors. An increase in histamine levels
has been noted in the skin and plasma of atopic dermatitis
patients (Johnson et al., 1960; Juhlin, 1967), and basophils
and mast cells are increased in atopic dermatitis lesions
(Phanuphak et al., 1980; Horsmanheimo et al., 1994;
Jarvikallio et al., 1997). Antihistamines that target the
histamine H1 receptor (H1R) are frequently used for the
treatment of atopic dermatitis-associated pruritus, but their
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effectiveness appears to be restricted to the first-generation
sedating H1R antagonists and non-sedating antihistamines
have little benefit (Akdis et al., 2006). This suggests that either
histamine is not involved in the disease pathophysiology or
that receptors other than the H1R may be important in
histamine-mediated responses in atopic dermatitis.
To explore this, we have used two potent and specific H4R
antagonists to examine the role of H4R in mediating
inflammation and pruritus in a Th2-cell-mediated mouse
skin inflammation model. The FITC skin model used here is a
contact dermatitis model, but it has been shown to be IgE-,
Th2 cytokine-, and CD4þ T-cell-dependent and is char-
acterized by strong eosinophilia, unlike other Th2 sensitizers
(Dearman and Kimber, 2000; Takeshita et al., 2004). Thus,
this model has several features similar to atopic dermatitis
in humans.
RESULTS
H4R antagonism inhibits edema in a dermal inflammation
model
Dermal inflammation was induced in BALB/c mice by topical
exposure to FITC (Figure 1a). Mice were sensitized to FITC by
painting on the abdomen on 2 consecutive days. After 5 days,
FITC was applied to one ear and 24 hours later the ear edema
was evaluated as an indication of inflammation. The H4R-
selective antagonist (Thurmond et al., 2004), JNJ 7777120,
administered 20minutes before and 4 hours after FITC
application reduced the ear edema in a dose-dependent
manner (Figure 1b). The maximum inhibition seen was 39%
and higher doses did not yield any further reduction. This
level of inhibition was similar to that seen using dexametha-
sone dosed at 3mg kg1, p.o. (orally) The role of the H4R in
this model is further supported by the reduction in ear edema
in H4R-deficient mice compared with wild-type mice (Figure
1c). In further support of an H4R-specific effect, a second H4R
antagonist, JNJ 28307474 (Table 1 and Supplementary
Materials), of a completely different chemical class was also
studied. This compound also inhibited ear edema formation
with a maximal effect similar to that found with JNJ 7777120
(Figure 1d). Although this compound does have some cross-
reactivity with muscarinic and 5-HT receptors (Supplemen-
tary Tables S1 and S2), the only affinity it shares in common
with JNJ 7777120 is at the H4R (Thurmond et al., 2004),
supporting the conclusion that the effects seen are mediated
through the H4R.
The inflammation in this model was also assessed by
histopathological analysis of the ears. At 24 hours after FITC
challenge, there was significant inflammation. This consisted
of mainly neutrophils, but there was also an increase in the
number of mast cells and eosinophils in the skin (Figures 2
and 3). The increase in mast cells and eosinophils is
consistent with a Th2 response in this model. Treatment with
the H4R antagonist led to a reduction both in the total severity
score and in the number of eosinophils and mast cells
(Figures 2 and 3).
In addition, the levels of several cytokines and chemokines
from ear homogenates were analyzed. A full time course was
carried out and all of the cytokine and chemokines levels
peaked at 12–18 hours (Figure 4). FITC application led to
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Figure 1. Histamine H4 receptor (H4R) antagonism reduces dermal
inflammation. (a) BALB/c mice (n¼ 7–14 mice per group) were sensitized to
FITC on days 0 and 1 and then challenged on day 6 by application of FITC to
one ear. On day 7, the difference in ear thickness between the challenged and
unchallenged ear was measured with calipers. (b) The H4R antagonist, JNJ
7777120, given p.o. (orally) 20minutes before and 4hours after FITC
application reduced swelling in a dose-dependent manner. The degree of
inhibition was similar to that of dexamethasone (Dex) given p.o. at 3mg kg1.
(c) Ear edema was reduced in H4R-deficient mice (H4R
/) compared with
wild-type (WT) mice. (d) Ear edema was also inhibited by a chemically
distinct H4R antagonist, JNJ 28307474, given p.o. 20minutes before and
4hours after FITC application. The degree of inhibition by JNJ 28307474
was similar to that of Dex given p.o. at 3mg kg1. **Po0.01; ***Po0.001
by one-way ANOVA using post hoc Bonferroni’s test compared
with vehicle (V) control for panels b and d and by Student’s t-test for
panel c.
Table 1. In vitro Ki for JNJ 28307474 histamine
receptor binding
Receptor Species Ki (nM)
1
H4 Human 4.9±1.1
H4 Mouse 109±8
H4 Rat 87±9
H4 Dog 62±31
H4 Guinea pig 3.4±0.6
H3 Human 159
H3 Rat 630
H1 Human 2,501
H1 Mouse 1,224±208
H1 Guinea pig 3,050
H2 Human 41,000
1Data given as ±SEM if the assay was run at least two times.
1024 Journal of Investigative Dermatology (2010), Volume 130
JM Cowden et al.
H4R Mediates Dermal Inflammation and Pruritus
increases in IL-4 levels, whereas IFN-g levels were low
(30–50 pgml1) and did not change with FITC treatment (data
not shown). This, along with the observed eosinophilia,
supports the previous findings that this model elicits a Th2
response (Dearman and Kimber, 2000; Takeshita et al.,
2004). In addition, there were increases in GM-CSF, IL-1b,
IL-6, tumor necrosis factor-a, RANTES, MCP-1, MIP-1a and
KC. IL-2, IL-9, and IL-12 were detected at low levels and
there was no change between control and FITC-treated ears
(data not shown). IL-10, IL-5, and IL-13 levels in the ear
homogenates were too low to measure. Treatment with the
H4R antagonist, JNJ 7777120, significantly reduced the levels
of MIP-1a, RANTES, IL-4, MCP-1, IL-1b, IL-6, KC, and
GM-CSF. Tumor necrosis factor-a was detected at low levels
in the FITC-challenged ears and this was significantly
reduced by treatment with JNJ 7777120. The inhibition of
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Figure 2. Histamine H4 receptor (H4R) antagonism reduces inflammation.
BALB/c mice (n¼ 7–14 mice per group) were sensitized to FITC on days 0 and
1 and then challenged on day 6 by application of FITC to one ear. On day 7,
ear specimens were taken for histology from (a) mice that were not exposed to
FITC, (b) mice exposed to FITC and treated with vehicle, (c) and mice exposed
to FITC and treated with 50mg kg1 JNJ 7777120. Bar¼ 100 mm for all.
(d) The total severity score was quantitated based on a 0–3 score for
inflammation, edema, and abscesses. **Po0.01 by Student’s t-test
comparing JNJ 7777120 with vehicle control.
*
***
α
ψ
Ce
lls
 p
er
 fi
el
d
15
10
5
0
EOS MC
Sh
am
Sh
amVe
h
Ve
h
JN
J
JN
J
Figure 3. Histamine H4 receptor (H4R) antagonism reduces the infiltration
of eosinophils. BALB/c mice (n¼7–14 mice per group) were sensitized to
FITC on days 0 and 1 and then challenged on day 6 by application of FITC to
one ear. On day 7, ear specimens were taken for histology, and the number of
eosinophils (EOS) was quantitated from (a) mice exposed to FITC and treated
with vehicle and (b) mice exposed to FITC and treated with 50mg kg1 JNJ
7777120 (JNJ). EOS are marked with a black arrow and mast cells with a red
arrow. Bar¼ 10mm for all. (c) Quantification of EOS and mast cells (MC) per
section. *Po0.05 and ***Po0.001 by one-way ANOVA with post hoc
Bonferroni’s test comparing JNJ 7777120 with vehicle control and cPo0.05
and aPo0.001 comparing sham with vehicle (Veh).
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the cytokine and chemokine levels was only partial, but this
was consistent with effects on tissue cytokines seen in lung
inflammation models (Dunford et al., 2006). Similar results
were seen with the other H4R antagonist, JNJ 28307474 (data
not shown). These results, along with the effect on ear edema
at 24 hours, clearly support a role for the H4R in Th2-
mediated skin inflammation.
Ex vivo antigen restimulation is impaired in
H4R-antagonist-dosed mice
FITC-induced dermatitis in BALB/c mice is suggested to be
CD4þ T-cell-dependent and Th2-driven (Dearman and
Kimber, 2000), and previous study has shown that the H4R
is involved in Th2 cell activation (Dunford et al., 2006). In
order to determine whether the H4R-mediated inflammation
in this model is due to effects on T-cell function, Th2 cytokine
levels were measured on ex vivo antigen stimulation of
lymph nodes. Draining lymph nodes were harvested after ear
edema measurements were taken. The total number of cells
in the draining lymph node of FITC-challenged mice was not
different between vehicle- and compound-treated mice, but
was increased compared with mice whose ears were not
challenged with FITC. An equal number of cells were then
cultured for 72 hours in the presence of FITC, and prolifera-
tion, as well as cytokine production, was measured. Cells
from draining lymph nodes isolated from FITC-exposed mice
proliferated with ex vivo FITC stimulation and this was
reduced in cells from the lymph nodes of mice dosed with JNJ
7777120 in vivo (Figure 5a). There was no change in
proliferation with anti-CD3/anti-CD28 stimulation, suggest-
ing that the effect was antigen-specific. After antigen
restimulation, the production of IL-4, IL-5, and IL-17 was
inhibited by treatment in vivo with JNJ 7777120 (Figure
5b–d). This result suggests that H4R antagonism impairs Th2
T-cell functions and this contributes to the decreases in
dermal inflammation in this model.
Dendritic cells migration is impaired by H4R antagonism
The above results suggest that H4R is involved in Th2-
dependent inflammatory responses. In order to better under-
stand the mechanisms involved, we tested the possibility that
H4R has a role in dendritic cell migration, as has been shown
in vitro for human monocyte-derived dendritic cells and
other cell types (Hofstra et al., 2003; Ling et al., 2004;
Gutzmer et al., 2005; Damaj et al., 2007). Antigen-bearing
dendritic cells were detected as positive for both FITC and
two dendritic cell markers—CD11c and MHC II. FITC-
positive dendritic cells were detected in the auricular lymph
nodes after FITC application on the ear (Figure 6a). Lymph
nodes from animals dosed with JNJ 7777120 contained a
lower number of FITC-positive dendritic cells and this was
evident with either CD11c or MHC II staining (Figure 6b
and c). These results suggest that the H4R is involved in the
control of the migration of antigen-carrying dendritic cells to
draining lymph nodes, and therefore can affect T-cell
priming.
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Figure 4. Histamine H4 receptor (H4R) antagonism reduces inflammatory cytokines in tissue. Ear tissues from mice that were sensitized and challenged
with FITC were harvested at various times after FITC challenge. The tissues homogenates were analyzed for cytokine and chemokine expression. Mice were
treated with either vehicle (white bars) or JNJ 7777120 (50mg kg1, p.o.; black bars). *Po0.05; and ***Po0.005 by Student’s t-test compared vehicle control at
each time point.
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Inflammatory pruritus is inhibited by an H4R antagonist
Previously, the H4R has been shown to be involved in mouse
models of acute pruritus. Because pruritus is a hallmark
feature of many inflammatory skin diseases such as atopic
dermatitis, studies were performed to see whether H4R
antagonists were anti-pruritic in a disease model. The model
(Figure 7a) was modified slightly from that used to assess
inflammation (Figure 1a) to yield a stronger itch component.
The scratching response in mice was attenuated by pretreat-
ment with JNJ 7777120 in a dose-dependent manner (Figure
7b). The H1R antagonist fexofenadine (Fex) given at a dose
(150mg kg1) previously shown to completely inhibit hista-
mine-induced edema formation (Dunford et al., 2007) had no
significant effect on pruritus alone, nor did it enhance the
effect of JNJ 7777120.
As for the previous model (Figure 1a), FITC application in
this model led to ear edema when measured 24 hours after
the challenge. JNJ 7777120 given 20minutes before and
4 hours after FITC application on the ear reduced the ear
edema in a dose-dependent manner (Figure 7c). The dose
response mimicked that seen with pruritus reduction. Again,
the effect of the H1R antagonist Fex in this model was studied
and given at a dose of 150mg kg1 did not show any
inhibition of ear edema (Figure 7c), nor was there any
additive effect when dosed in combination with JNJ
7777120. This indicates that an H4R antagonist, but not the
H1R antagonist, can have both anti-inflammatory and anti-
pruritic effects in this model.
To assess whether the effect of the H4R antagonists was
dependent on mast cells, the extended FITC model (Figure
7a) was carried out in mast-cell-sufficient (WBB6F1þ /þ ) and
mast-cell-deficient (WBBF1 W/Wv) mice. FITC application
was able to induce edema and scratching in mast-cell-
deficient mice and both could be inhibited by JNJ 7777120
(Figure 7d and e). This indicates that mast cells are not
required for the H4R-mediated responses and that they are
not the source of histamine for activating the H4R. Interest-
ingly, although the edema was equivalent in both the mast-
cell-deficient and wild-type animals, the scratching was
much greater in the mast-cell-deficient mice. The mechan-
isms for this are unknown, but it has been seen previously
with both substance P and compound 48/80 induced itch,
although to a lesser extent (Inagaki et al., 2002; Hossen et al.,
2003). Recently, it has been recognized that mast cells can
have both negative and positive regulatory functions depend-
ing on the physiological situation (Galli et al., 2008).
DISCUSSION
Histamine has been implicated in the pathophysiology of
atopic dermatitis, but antihistamines that target the H1R are
generally not considered to be effective (Akdis et al., 2006).
In this study, we have used a mouse model to test the efficacy
of H4R antagonists against allergic inflammation and pruritus
in the skin. FITC challenge is a contact dermatitis model, but
it has several features similar to atopic dermatitis, in that it is
IgE-, Th2 cytokine-, and CD4þ T-cell-dependent (Dearman
and Kimber, 2000; Takeshita et al., 2004). In particular, the
model is characterized by strong eosinophilia that distin-
guishes it from other Th2 sensitizers (Figure 3 and Takeshita
et al., 2004). In this study, we have confirmed the Th2 nature
of this model by showing increases in eosinophils, mast cells,
and Th2 cytokines in the ear after FITC challenge.
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Figure 5. Histamine H4 receptor (H4R) antagonism reduces T helper type 2 (Th2) cell responses. Peripheral lymph nodes were collected 24hours after FITC
challenge from mice treated with vehicle (white bars) or JNJ 7777120 (50mg kg1, p.o.; black bars). Lymphocytes were isolated and cultured with either
10mgml1 FITC or a combination of anti-CD3 and anti-CD28. (a) Proliferation was measured by 3H-thymidine incorporation after 96 hours. (b–d) IL-4, IL-5, and
IL-17 levels were measured after 72 hours using ELISA. **Po0.01 by Student’s t-test compared with vehicle control.
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Previous study has suggested that the H4R modulates
allergic lung inflammation mainly through its effects on Th2
cell induction. The data shown here show that this is also true
for Th2 responses in the skin. The levels of several
proinflammatory cytokines and chemokines including IL-4
were increased in ear tissue on FITC challenge and were
inhibited by treatment with H4R antagonists. Although the
effects of dexamethasone on cytokine production were not
studied, it has recently been shown that it also can reduce the
tissue levels of IL-4 in this model (Boehme et al., 2009). The
reduction in these inflammatory mediators may lead directly
to an attenuation of edema formation, as it has been
previously shown that blocking IL-4 and tumor necrosis
factor-a can decrease edema in this model (Takeshita et al.,
2004; Suto et al., 2006). In addition, the number of mast cells
and eosinophils in the ear were increased on exposure to
FITC and the levels of both of these could be reduced by
treatment with H4R antagonists. The effects on mast cells and
eosinophils could be an indirect effect because of changes in
cytokine or chemokine levels, or could be a direct effect as
the H4R has been shown to mediate chemotaxis for both of
these cell types (Hofstra et al., 2003; Ling et al., 2004).
In particular, it has been shown in vivo that histamine can
induce mast cell migration in the trachea and that this can be
blocked by an H4R antagonist (Thurmond et al., 2004).
A direct role for the H4R on Th2 cell function was seen
after antigen restimulation of draining lymph nodes from
FITC-treated animals. Restimulation with FITC resulted in a
profound increase in proliferation of cells from these mice
compared with that from sham animals, which was sig-
nificantly inhibited in lymph nodes taken from animals dosed
with JNJ 7777120. However, proliferation in response to anti-
CD3/anti-CD28 stimulation was not affected. Similarly,
stimulation of the lymphocytes with either FITC or anti-
CD3/anti-CD28 led to the production of the Th2 cytokines
IL-5 and IL-4. The production of these cytokines on FITC
stimulation, but not on anti-CD3/anti-CD28 stimulation, was
significantly inhibited in lymph nodes taken from animals
given JNJ 7777120. In addition, IL-17 was also produced on
antigen restimulation and this was inhibited by in vivo treat-
ment with JNJ 7777120. Similar results have been reported in
a mouse allergic lung inflammation model (Dunford et al.,
2006). These results suggest that with regard to the lung, the
H4R can modulate Th2 T-cell responses in the skin.
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In the previous study, it was shown that H4R on dendritic
cells was necessary for proper stimulation of Th2 cells in vitro
(Dunford et al., 2007). Therefore, some of the effects of H4R
antagonists on in vivo Th2 responses may be directly related
to the activation of Th2 cells. In addition to this, it appears
that the H4R can mediate migration of dendritic cells from
sites of inflammation to the lymph nodes. Dendritic cells and
Langerhans cells in the skin are important antigen-presenting
cells necessary for the activation of T cells and are known, at
least in the case of dendritic cells, to express the H4R.
Recently, it has been shown that the H4R is expressed on
human inflammatory dendritic epidermal cells that are found
in lesions of atopic dermatitis patients (Dijkstra et al., 2008).
After activation, antigen-presenting cells migrate from the site
of inflammation to the draining lymph nodes, where they
interact and activate T cells. In this model, treatment with an
H4R antagonist reduced the number of FITCþ dendritic cells
in the draining lymph nodes. Therefore, the reduction in the
number of antigen-presenting cells migrating to the lymph
node with H4R antagonism may contribute to a reduction in
Th2 cell activation.
The effect on the number of dendritic cells in the lymph
nodes may be an indirect effect related to the reduction in
tissue cytokines and chemokines by H4R antagonism. In
particular, tumor necrosis factor-a, IL-1b, GM-CSF, and
MCP-1 have all been shown to mediate dendritic cell or
Langerhans cell migration from the skin to the lymph node
(Cumberbatch and Kimber, 1995; Cumberbatch et al., 1997,
1999, 2000, 2003; Smith et al., 1998; Mizumoto et al., 2001;
Suto et al., 2006). In addition to the potential indirect effect,
histamine acting through the H4R directly on human
monocytes-derived dendritic cells or mouse bone-marrow-
derived dendritic cells has been shown to induce chemotaxis
in vitro (Gutzmer et al., 2005; Damaj et al., 2007; Ba¨umer
et al., 2008). Furthermore, Ba¨umer et al. (2008) have
recently shown that histamine can enhance dendritic cell
migration from mouse ear explants and that this effect could
be blocked by JNJ 7777120. Therefore, histamine can
directly induce chemotaxis or can prime dendritic cells for
activation by other chemokines to promote migration to the
lymph nodes. Decreased dendritic cell migration to the
lymph nodes should lead to reduced activation of T cells
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Figure 7. Histamine H4 receptor (H4R) antagonism reduces pruritus. (a) BALB/c mice (n¼ 7–14 mice per group) were sensitized to FITC on days 0, 1, 13,
and 14 and then challenged on day 20 by application of FITC to one ear. Bouts of scratching were measured for 15minutes starting 10minutes after FITC
application, whereas the difference in ear thickness between the challenged and unchallenged ear was measured on day 21. (b) The H4R antagonist, JNJ
7777120, given p.o. 20minutes before FITC application reduced the pruritus, whereas the H1R antagonist fexofenadine (Fex) given at 150mg kg
1, p.o. had
no effect. (c) The H4R antagonist, JNJ 7777120, given p.o. 20minutes prior to and 4 hours after FITC application reduced the swelling induced by FITC challenge
in the model given in panel a, whereas the H1R antagonist Fex given at 150mg kg
1, p.o. had no effect. (d and e) The model given in panel a was carried out
in mast-cell-sufficient (WBB6F1þ /þ ; white bars) and mast-cell-deficient (WBBF1 W/Wv; black bars) mice. The H4R antagonist, JNJ 7777120, given p.o.
20minutes prior and 4 hours after FITC application reduced the pruritus (d) and edema (e) in the mast-cell-sufficient and -deficient mice. **Po0.01; ***Po0.005
by one-way ANOVA with post hoc Bonferroni’s test compared with vehicle (V) control.
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consistent with the reduction in T cells in the tissue and
cytokine production.
The effects of the H4R antagonists on Th2 cytokines
appeared to translate into a reduction in ear edema on
application of FITC. The inhibitory effect on edema is clearly
H4R-mediated as two chemically distinct compounds show
equivalent effects and similar effects are seen in H4R-deficient
mice. However, this reduction was only partial, indicating that
only a portion of the edema is H4R-mediated. This is consistent
with a previous report showing that blocking the T-cell
cytokines IL-4 or IL-5 in this FITC model only gives a partial
reduction in ear edema at 24hours (Takeshita et al., 2004).
Interestingly, the inhibition seen with either H4R antagonist
was equivalent to that seen with dexamethasone.
In addition to the anti-inflammatory effects of H4R
antagonists, this study shows that the compounds were also
anti-pruritic in this mouse model of allergic skin inflamma-
tion. Histamine has long been known to be a mediator of itch
in normal human skin and it induces increased pruritic
responses in the diseased skin of atopic dermatitis patients
compared with those in normal skin (Steinhoff et al., 2003).
However, the role of histamine in the pruritus associated with
atopic dermatitis is much less clear mainly due to the fact that
H1R antihistamines are generally considered to be ineffective
in the treatment of atopic dermatitis-associated pruritus (Klein
and Clark, 1999; Akdis et al., 2006). Previous study has
shown that the H4R receptor is involved in acute pruritus in
mice induced by histamine, mast cell degranulation, or direct
stimulation of neurons (Dunford et al., 2007). In the model
presented here, the reduction in pruritic responses may be
due to a reduction in inflammation or due to a direct effect on
sensory neurons, as postulated for the acute pruritus models.
It is of interest that both the edema and pruritic responses
to FITC are retained in the W/Wv mice and that the H4R
antagonist was still able to block both responses. This
suggests that mast cells are not required for either the H4R-
mediated edema or pruritic responses, although care should
be take with this interpretation as these mice still have some
skin mast cells (o1% of the wild-type levels) and have other
defects including a slight neutropenia that may affect the
response (Tsai et al., 2005; Nigrovic et al., 2008). The mast-
cell-independent effects of the H4R on the edema and
pruritus in this model are consistent with previous data in a
mouse asthma model and other pruritus models (Dunford
et al., 2006, 2007). However, the mechanism for the
development of pruritus immediately after the application
of FITC in the absence of mast cells in unknown. It is possible
that it triggers histamine or other mediator production from
other cells such as dendritic cells or keratinocytes. Intrigu-
ingly, it was recently shown that the H4R can mediate the
production of IL-31 (Gutzmer et al., 2009) and this cytokine
has been linked to pruritus in atopic dermatitis (Dillon et al.,
2004; Castellani et al., 2006). In addition, these data suggest
that mast cells are not the source of histamine that activates
the H4R. Several other cell types in the skin have been shown
to have the capacity to produce histamine on stimulation
including dendritic cells and keratinocytes (Malaviya et al.,
1996; Dunford et al., 2006).
In this study, it is shown that the H1R antagonist Fex is not
effective against either the inflammatory or pruritic responses
in this model. The lack of effect on pruritus is consistent with
the previous findings in acute pruritus models (Dunford et al.,
2007) and with the lack of effect of second-generation
antihistamines, including Fex, on itch in atopic dermatitis
patients (Klein and Clark, 1999). Furthermore, the fact that
the H1R antagonist cannot block the FITC-induced edema
indicates that histamine itself is probably not driving this
response, as this dose of Fex can completely inhibit
histamine-induced edema (Dunford et al., 2007). However,
these conclusions should be taken with caution because they
may depend on the H1R antagonist used. For example,
diphenhydramine has been shown to block histamine and
antigen-induced itch, which is believed to be due to its
central activity (Dunford et al., 2007; Rossbach et al., 2009).
It has also been shown that loratadine can inhibit histamine-
induced itch, whereas Fex does not; however, neither appear
to inhibit compound 48/80-induced scratching (Hossen et al.,
2005; Dunford et al., 2007). Whether these differences have
to do with the differences in distribution such as central
nervous system penetration or perhaps non-H1R-related
effects of the compounds is not known.
While this paper was being prepared, another study
appeared addressing the effects on JNJ 7777120 on the
pruritus induced by two other haptens, 2,4-dinitrochloroben-
zene and toluene-2,4-diisocyanate (Rossbach et al., 2009).
Consistent with the data shown in this study, JNJ 7777120
was able to significantly inhibit the pruritus induced by either
hapten. However, the edema formation 24 hours after hapten
challenge was not affected. The difference between our
finding and those reported in this study regarding the anti-
inflammatory properties of H4R antagonists are unclear, but
may reflect differences in mouse strains used or in the
mechanism of action of the haptens. This is especially true for
2,4-dinitrochlorobenzene, which is described as inducing a
Th1-dependent effect (Rossbach et al., 2009). In particular,
the FITC model used in this study has a strong eosinophil
component that is not found in other contact dermatitis
models (Figure 3 and Takeshita et al., 2004). Eosinophilic
inflammation may be particularly sensitive to H4R antagon-
ism as it has been shown that eosinophil chemotaxis can be
directly mediated by the H4R (Buckland et al., 2003; Ling
et al., 2004) and reductions in eosinophils have also been
seen in asthma models (Dunford et al., 2006). The results
presented here are also consistent with the effects of
thioperamide, a dual H3R/H4R antagonist, in reducing edema
and eosinophil infiltration in another skin inflammation
model (Hirasawa et al., 2009).
These data presented in this study show an effective anti-
pruritic and anti-inflammation function of H4R antagonists in
a mouse model of Th2-dependent skin inflammation. This
effect was superior to that of H1R antagonists. The anti-
inflammatory properties appeared to be driven by a reduction
in Th2 cell activation that can be partially accounted for by a
reduction in the migration of antigen-bearing dendritic cells
to the lymph nodes. Therefore, the effects of the H4R
antagonists on pruritus, inflammation, and Th2-cell responses
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point to their therapeutic potential for the treatment of
inflammatory skin disorders such as atopic dermatitis.
MATERIALS AND METHODS
Mice
BALB/c mice were obtained from Charles River Laboratories
(Wilmington, MA). WBB6F1þ /þ and WBBF1 W/Wv mice were
purchased from Jackson Laboratory (Bar Harbor, Maine). H4R-
deficient mice were generated as previously described (Hofstra
et al., 2003) and crossed on to a BALB/c background for at least 10
generations. Age-matched animals were used in all experiments.
Mice were housed in community cages on a 12-hour light cycle and
fed mouse chow and water ad libitum. All procedures were
performed according to the internationally accepted guidelines for
the care and use of laboratory animals in research and were approved
by the local Institutional Animal Care and Use Committee.
Materials
JNJ 7777120 (5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-
methanone) and JNJ 28307474 (5-fluoro-4-methyl-2-{5-methyl-
2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimida-
zole were synthesized as previously described (Jablonowski et al.,
2003; Arienti et al., 2005). FITC, dexamethasone, Fex, and
dibutylphthalate were obtained from Sigma-Aldrich (St Louis, MO).
The selectivity of JNJ 7777120 has been previously described
(Thurmond et al., 2004). The selectivity of JNJ 28307474 is given
in Table 1 and Supplementary Tables S1 and S2. The binding
assays were carried out as previously described (Thurmond et al.,
2004).
FITC model
Female mice (6- to 8-week olds) were used. The abdomen of each
animal was shaved and sensitized by the application of 100 ml of
FITC in dibutylphthalate and acetone on 2 consecutive days. At 5
days after sensitization, the baseline thickness of the ears was
measured using calipers with the animals under light isofluorane
anesthesia. One ear was then painted with 15 ml of FITC and the
contralateral ear was painted with vehicle (dibutylphthalate/acet-
one). Finally, the thickness of the ears was measured again 24 hours
after FITC application. Animals were then euthanized and biopsies
of the ear collected. In addition, a repeat sensitization model was
also performed, in which animals were sensitized on days 1, 2, 15,
and 16 and challenged on day 21. The thickness of the ears was
measured again 24 hours after FITC application.
Compound administration
All compounds were formulated in 2-hydroxypropyl-b-cyclodextrin
for all experiments and were administered p.o. 20minutes before
FITC challenge and 4hours after challenge.
Histology
For histological examination, ear specimens were fixed in 10%
buffered formalin and embedded longitudinally in paraffin by
standard methods. Sections of 4mm thickness were stained with
Wright–Giemsa stain. Individual parameters such as inflammation,
edema, and the number of abscesses were assessed and scored
as follows:
Inflammation.
K 0: no visible inflammation;
K 1: inflammatory cells present along o40% of the length of the
skin;
K 2: inflammatory cells present between 40 and 80% of the length
of the skin; and
K 3: inflammatory cells present along 480% of the length of the
skin.
Edema.
K 0: no edema;
K 1: increase in relative thickness from normal by 20%;
K 2: increase in relative thickness from normal by 20–40%; and
K 3: increase in relative thickness from normal more than 40%.
Abscesses.
K 0: no abscesses;
K 1: o2;
K 2:o4; and
K 3: X4.
A total severity score was obtained by adding the scores from the
three assessments above. The theoretical maximum severity score
was nine. The score was determined from six whole sections from
each animal. In addition, the number of eosinophils and mast cells
were quantitated from eight randomly selected high-power fields
from four sections for each animal.
Cytokine measurements in ear tissue
Skin ear biopsies were pooled from four test animals. Biopsies were
minced and then repeatedly homogenized with beads in phosphate-
buffered saline (PBS) plus Complete Protease Inhibitor Cocktail
(Roche Applied Science, Indianapolis, IN) at 4 1C. Supernatant was
collected and analyzed for the presence of cytokines using a
Luminex multiplex system (Luminex, Austin, TX) with a Mouse
Cytokine LINCOplex Panel (Millipore, Billerica, MA) as per the
manufacturer’s protocol (mouse twenty-two cytokine kit).
FITC-specific T-cell responses in vitro
Auricular lymph node cells were isolated from immunized mice,
pooled, and cultured in quadruplicate (5 105 cells per well) with
medium (RPMI 1640 supplemented with 10% fetal bovine serum,
non-essential amino acids and b-mercaptoethanol) alone or with
medium plus 10mgml1 FITC (diluted from 10mgml1 stock in
100% DMSO) for 96 hours. Cell culture supernatants were collected
after 3 days, and cells were continued in culture with [3H]-thymidine
(1mCi per well) for another 18 hours for proliferation assays.
[3H]-Thymidine uptake was quantitated by liquid scintillation
counting. Cytokine levels in cell culture supernatants were
determined using a Luminex multiplex system (Luminex) with a
Bio-Rad Bioplex (Hercules, CA) or Mouse Cytokine LINCOplex
Panel (Millipore) as per the manufacturer’s protocol (mouse eighteen
or twenty-two cytokine kit, respectively). For anti-CD3/anti-CD28
stimulations, 96-well plates were coated with 100ml per well of
10 mgml1 anti-mouse CD3 (NA/LE) (BD Pharmingen, San Diego,
CA) in PBS, incubated overnight at 4 1C. Before adding cells, the
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wells were aspirated and washed twice with PBS. After the addition
of cells (5 105 cells per well), anti-mouse CD28 (NA/LE) (BD
Pharmingen) was added to a final concentration of 2 mgml1 and
incubated for 72 hours before processing as above for proliferation
and cytokine production.
Dendritic cell migration in vivo
Mice were shaved and sensitized by application of 100ml of 0.5%
FITC in dibutylphthalate and acetone onto the abdomen on 2
consecutive days. At 5 days after the sensitization, animals
were dosed with compounds, and 30minutes later, one ear was
painted with 15 ml of 0.5% FITC on both sides and the control ear
was painted with vehicle (dibutylphthalate/acetone). At 24 hours
after the application of FITC, auricular lymph nodes were
removed, and digested with 2.5ml digestion buffer (RPMI 1640
containing 50 ml of DNase I (Sigma-Aldrich) and Liberase III (Roche
Applied Science, Indianapolis, IN)) for 20minutes at 37 1C. Fresh
digestion buffer (2.5ml) was added and incubated for another
15minutes at 37 1C. Lymph nodes were gently dispersed with a
70-mm cell strainer, flushed with 5ml PBS containing 5mM EDTA,
spun down, washed once with 5ml PBS containing 5mM EDTA, and
resuspended in 10ml FACS buffer (PBS with 1% fetal calf serum).
Cells were counted and adjusted to 1 107 cells per ml and
1–2 106 cells were used for each staining. Cells were incubated
with 1:50 FcR blocker (BD Pharmingen, San Diego, CA) on ice for
15minutes, stained with 1:50 PE-anti-CD11c or PE-anti-I-Ad (BD
Pharmingen) for 45minutes on ice. Cells were washed once with
3ml FACS buffer, resuspended, and collected on FACSCalibur
(BD Biosciences Immunocytometry Systems, San Jose, CA). Before
analysis, 1mgml1 propidium iodide was added to stain for
dead cells.
Pruritus assessment
Pruritus was quantified by counting the number of bouts of
scratching in a 15-minute period starting 10minutes after the
application of FITC to the ear. Bouts of scratching were recorded
and defined as previously described (Dunford et al., 2007).
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